A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis

The purpose of this study is to evaluate the efficacy and safety of KLH-2109 in patients with endometriosis.

Completed

Looking for future studies?

Key information

Conditions

Endometriosis Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Urogenital Diseases

Age range

20 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Japan

Tokyo and Other Japanese City, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Female patients with endometriosis

Exclusion criteria

Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Treatment and study plan

KLH-2109

Drug

Primary outcomes

The severity score of the pelvic pain

Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

Kissei Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Multicenter, Randomized, Open Label Phase II Study of KLH-2109 in Patients With Endometriosis(3)

Important dates

First posted: Jun 27, 2012
Registry last updated: May 30, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed